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Abstract
Polygenic scores can be used to distil the knowledge gained in genome-wide association studies for prediction of health,
lifestyle, and psychological factors in independent samples. In this preregistered study, we used fourteen polygenic scores to
predict variation in cognitive ability level at age 70, and cognitive change from age 70 to age 79, in the longitudinal Lothian
Birth Cohort 1936 study. The polygenic scores were created for phenotypes that have been suggested as risk or protective
factors for cognitive ageing. Cognitive abilities within older age were indexed using a latent general factor estimated from
thirteen varied cognitive tests taken at four waves, each three years apart (initial n= 1091 age 70; ﬁnal n= 550 age 79). The
general factor indexed over two-thirds of the variance in longitudinal cognitive change. We ran additional analyses using an
age-11 intelligence test to index cognitive change from age 11 to age 70. Several polygenic scores were associated with the
level of cognitive ability at age-70 baseline (range of standardized β-values= –0.178 to 0.302), and the polygenic score for
education was associated with cognitive change from childhood to age 70 (standardized β= 0.100). No polygenic scores
were statistically signiﬁcantly associated with variation in cognitive change between ages 70 and 79, and effect sizes were
small. However, APOE e4 status made a signiﬁcant prediction of the rate of cognitive decline from age 70 to 79
(standardized β= –0.319 for carriers vs. non-carriers). The results suggest that the predictive validity for cognitive ageing of
polygenic scores derived from genome-wide association study summary statistics is not yet on a par with APOE e4, a better-
established predictor.
Introduction
Mean levels of several cognitive functions decline as people
grow older, even in those without dementia. This is
observed for many important cognitive abilities, such as
memory, processing speed, and reasoning [1–3], with so-
called “crystallized” abilities, such as vocabulary, less
affected. There is strong evidence that age-related declines
across all abilities are correlated: cognitive ageing, as with
individual differences in cognitive ability level, is sub-
stantially a general phenomenon [4–6]. Declines in cogni-
tive abilities in older age have practical consequences for
daily life and independent living: they have been linked to
lower ability to perform everyday functions such as
understanding medicine labels [7], and to increased vul-
nerability to ﬁnancial fraud [8, 9]. Discovering predictors of
variation in cognitive ageing might help us to identify those
at highest risk of more rapid decline, and—to the extent that
such predictors are conﬁrmed to be causal—devise appro-
priate interventions. In the present study, we assessed the
value of a panel of genetic risk scores in predicting variation
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in general cognitive decline in a generally healthy sample
across the eighth decade of life.
Many studies have investigated whether variables that
are known to correlate cross-sectionally with cognitive
ability are also predictive of variation in its decline.
Numerous such factors have been tested, but few have been
replicated consistently [10]. For instance, although higher
educational attainment has been found in some studies to
predict shallower rates of cognitive decline [11, 12]—a
ﬁnding which has informed theories of “cognitive reserve”
[13]—other studies have not found this same effect [14, 15].
Other potential predictors, with varying degrees of evi-
dentiary support, and a great deal of methodological het-
erogeneity, include physical ﬁtness, as measured by
variables such as grip strength and lung function [16, 17]
(see ref. [18] for a review), personality traits such as con-
scientiousness [19] (see ref. [20] for a review), and type 2
diabetes [21] (see ref. [22] for a review).
Here, we investigate potential genetic predictors of
cognitive level at age 70, and relative cognitive decline
from age 11 to 70 years, and from age 70 to 79 years.
One such predictor is well-known already: carriers of either
one or two APOE e4 alleles (as opposed to no such alleles)
are not just at higher risk of a diagnosis of Alzheimer’s
disease [23, 24], but also appear to be at risk of steeper
cognitive decline [25]. In recent years, however, a new
method has become commonly used in research investi-
gating genetic prediction of traits: the calculation of poly-
genic scores. This method uses summary data from
published genome-wide association studies (GWAS) that
have tested the correlations of millions of single-nucleotide
polymorphisms (SNPs) with phenotypes of interest. Using
the weightings (regression coefﬁcients) for each SNP from
these data, genotyped individuals in an independent sample
(one not included in the original GWAS) can have a
polygenic score (PGS) calculated that indexes the cumula-
tive small effects that produce a genetic liability to a certain
disease, or a probability of a higher level of a particular trait
[26]. Through meta-analysis, and through the collection of
ever-larger datasets, the sample size, and thus the statistical
power, of GWAS studies continues to increase. For exam-
ple, the variance explained in educational attainment in
independent samples by the educational attainment PGS has
increased alongside the sample size of the discovery
GWASs [27, 28].
PGSs can be used to predict variables other than their
“own” phenotype. The PGS for educational attainment, for
example, has been shown not just to predict educational
attainment but also, among other variables, cognitive ability
[29], the rate of cognitive development in childhood [30],
social mobility [30, 31], and longevity [32]. It is possible,
then, that the genetic variants linked to phenotypic
predictors of the cognitive ability or relative cognitive
decline may also themselves predict later-life decline [33].
Indeed, a number of papers have found links between
various disease-linked polygenic scores and older age
cognitive ability, including some indications at earlier
data-collection waves of the same sample examined here
[34–37].
Testing PGSs as predictors of outcomes such as cogni-
tive level and change is potentially useful and efﬁcient.
Researchers or clinicians can use a single source material—
a participant’s DNA—to test their genetic propensity to a
very wide range of risk and protective factors [38]. There-
fore, instead of having to measure all the phenotypes that
might confer risk to or protection of cognitive decline, it
might be possible—to the extent that those phenotypes are
heritable and have had a large, high-quality GWAS per-
formed—to assess the genetic propensity to the phenotype
and use that information to predict cognitive level and
decline. The approach using PGSs, if successful, would also
allow the retrospective testing of risk and protective factors
in cohorts where DNA and longitudinal cognitive data are
available but who were never tested for the risk or protec-
tive factors in question. Beyond these potential strengths,
PGSs can even be used to assess propensity to a phenotype
that is never expressed, such as liability to schizophrenia in
a sample in which no one develops the illness [26]. Finally,
understanding the genetic variants that are and are not
shared among different traits and disorders may provide
clues to their biological aetiologies.
We selected fourteen PGSs based on, ﬁrst, the relevant
phenotype having been linked to cognitive decline in at
least one previous study and, second, on there being a
recent GWAS of that phenotype (Table S1 provides a list of
references to the phenotypic studies, and to the respective
GWASs). The PGSs in question were those for the fol-
lowing variables: educational attainment, the personality
traits of neuroticism and conscientiousness, Alzheimer’s
disease, Parkinson’s disease, schizophrenia, major depres-
sive disorder, coronary artery disease, stroke, type 2 dia-
betes, smoking, height, body mass index, lung function, and
grip strength. We tested the associations of each of these
PGSs with the level (at age 70 years) and age-related slope
(from age 70 to age 79 years) of general cognitive ability
estimated from a battery of thirteen varied tests. We added a
further analysis where we tested the association of the PGSs
with the change between a cognitive test taken at age 11 and
age-70 general cognitive ability. We tested their predictive
value individually, simultaneously, and—because the pre-
sence of the APOE e4 allele has previously been found to
predict cognitive decline in this same cohort during almost
the same period of life [5]—in models also including the
APOE e4 status of the participants.
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Methods
Sample
The Lothian Birth Cohort 1936 (LBC1936) is an ongoing
longitudinal study of older, community-dwelling indivi-
duals living mostly in the Edinburgh and Lothians area of
Scotland, UK [39, 40]. They were recruited on the basis of
their having been part of the Scottish Mental Survey of
1947 [41], and have, to date, attended four testing waves:
the ﬁrst at mean age 69.54 years (SD= 0.83; n= 1091; 543
females), the second at age 72.52 years (SD= 0.71; n=
866; 418 females), the third at age 76.25 years (SD= 0.68;
n= 697; 337 females), and the fourth at age 79.32 (SD=
0.62; n= 550; 275 females). For simplicity, we will hen-
ceforth refer to the ages at each wave as 70, 73, 76, and 79
years, respectively. Ethical approval for the LBC1936 study
came from the Multi-Centre Research Ethics Committee for
Scotland (MREC/01/0/56; 07/MRE00/58) and the Lothian
Research Ethics Committee (LREC/2003/2/29). All parti-
cipants, who were volunteers and received no ﬁnancial or
other reward, completed a written consent form before any
testing took place.
Cognitive measures
In addition to completing the Moray House Test No. 12
at age 11 years [42], which measures a variety of
cognitive domains with an emphasis on verbal reasoning,
the LBC1936 members completed a wide selection of
cognitive tests at each of the later-life testing waves. Tests
were administered identically at each occasion. Thirteen
tests were used for the present analysis, covering the four
broad cognitive domains described below. Participants also
completed the Mini-Mental State Examination (MMSE)
[43] at each wave; results from wave 1 were used to validate
the Alzheimer’s disease PGS (see below).
Visuospatial ability was measured using tests of pattern-
based reasoning, recognition, and recall: the Matrix Rea-
soning and Block Design subtests of the Wechsler Adult
Intelligence Scale, 3rd UK Edition (WAIS-IIIUK [44]), and
the Spatial Span subtest of the Wechsler Memory Scale, 3rd
UK Edition (WMS-IIIUK [45]; the score used here was an
average of forwards and backwards spatial span).
Verbal memory was measured using three tests of recall
of new verbal information: the Logical Memory and Verbal
Paired Associates subtests of the WMS-IIIUK (both indi-
cated by their total score), and the Digit Span backwards
subtest of the WAIS-IIIUK.
Crystallized ability was measured by three tests: the
National Adult Reading Test (NART [46]), the Wechsler
Test of Adult Reading (WTAR [47]) and a test of phonemic
verbal ﬂuency [48]. All three tests assessed prior verbal
knowledge.
Processing speed was measured using four tests tapping
cognitive speed in a variety of ways. Two of the tests were
pencil-and-paper “clerical” tasks: the Digit-Symbol Sub-
stitution and Symbol Search tasks from the WAIS-IIIUK. A
third was a psychophysical measure of Inspection Time
performed on a computer monitor (as described in ref. [49]).
A fourth was a test of Choice Reaction Time, measured
using the dedicated button-box described in ref. [50]. Note
that, in each of the analyses, we reversed scores on the
Choice Reaction Time test so that higher scores indicated
better (faster) cognitive performance.
Genetic measures
The majority of participants provided blood samples at the
age 70 wave that were used to extract DNA for the genetic
analyses. To measure single-nucleotide polymorphisms
(SNPs) we used the Illumina 610-Quadv1 whole-genome
SNP array; measurements were completed at the Wellcome
Trust Clinical Research Facility Genetics Core, Western
General Hospital, Edinburgh. Polygenic scores (PGSs) were
created using PRSice software [51], with linkage-
disequilibrium clumping parameters set to r2 > 0.25 over
250 kb sliding windows. All PGSs were calculated using all
SNPs from their respective GWAS (see Table S1 for all
references and discovery sample sizes); that is, we used an
association threshold of p ≤ 1.00. In three cases (smoking,
lung function, and grip strength), we ran a new GWAS on
data we had available from the UK Biobank sample
(see Supplementary Method and Figures S1–S3). This was
either because this resulted in a larger GWAS than the most
recent published GWAS at the time, or because the
LBC1936 participants were included in that most recent
GWAS. In addition to the PGS analyses, each participant’s
APOE e4 genotype was ascertained using TaqMan tech-
nology, also at the Wellcome Trust Clinical Research
Facility Genetics Core. Since there were few carriers of two
APOE e4 alleles (~2% of the sample), we categorised this
variable as the binary presence (306 participants; ~30%) or
absence (722 participants; ~70%) of any APOE e4 alleles.
Statistical analysis and preregistration
In a set of preliminary analyses, we estimated whether
each polygenic score was signiﬁcantly associated with its
“own” phenotype in the Lothian Birth Cohort. We
selected phenotypes that were as closely-related as pos-
sible given the data we had available. The selected
phenotypes were as follows. For the education PGS, we
used years of education, reported at age 70. For the
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Neuroticism and Conscientiousness PGSs, Neuroticism
and Conscientiousness were estimated using the NEO-FFI
personality instrument [52], self-reported at age 70. For
the Alzheimer’s disease we used the scores on the MMSE,
and for the Schizophrenia PGS, we used WAIS-III Block
Design (since this test provided an estimate of cognitive
ability, which is impaired in schizophrenia; no test of
schizophrenia symptoms was available). For the major
depressive disorder PGS, we used the score on the
depression subscale of the Hospital Anxiety and Depres-
sion Scale (HADS [53]), taken at age 70. For the coronary
artery disease, stroke, and type 2 diabetes PGSs, we used
self-reports of whether the participants had ever received a
diagnosis of any of these conditions by age 70. For the
smoking PGS, we used a self-report of whether the par-
ticipant was a never-, ex-, or current smoker at age 70. For
the height and BMI PGSs, we used the measurements of
these traits taken by nurses at the age-70 testing wave.
Finally, for the FEV1 and grip strength PGSs, we used the
measurements of these physical functions taken at age 70
using a spirometer and a dynamometer, respectively.
The analyses described below were preregistered, except
for the ﬁnal one (including age-11 intelligence scores to
estimate lifetime cognitive change), which, therefore,
should be considered as exploratory. The time-stamped
preregistration document, written after data from the fourth
testing wave of LBC1936 were collected and entered into
the database, but before any of these data had been seen by
any of the analysts of this study, can be found at the fol-
lowing URL: https://osf.io/vyy4u/.
Before analysing any of the cognitive data, we used a
parallel analysis, using the psych package for R [54], to
factor-analyse the PGSs, testing whether there was evidence
for a general factor (as there is for cognitive tests). If evi-
dence of such a general factor emerged, we planned to
assess the value of this general factor as a predictor in the
cognitive models.
We estimated a “factors of curves” structural equation
model to characterise cognitive levels and changes within
older age. This involved estimating a latent growth curve
model for each cognitive test, then factor-analysing the
latent intercepts and latent slopes from these models.
The model follows the same structure as that of ref. [5],
where we used data from the ﬁrst three waves of the
LBC1936 to examine predictors of cognitive change from
age 70 to 76 years. The factor models for both levels and
slopes were hierarchical, as shown in Fig. 1: there were
four domain-level factors estimated for both level and
slope (Visuospatial ability, Verbal Memory, Crystallized
ability, and Processing Speed), which were themselves
factor-analysed to produce the general factors of cognitive
level and slope. Squaring the product of each test’s
loading on its domain and the domain’s loading on the
general factor provided a proportion of variance in each
test explained by the general factor; averaging these
values produced the mean amount of variance explained
at each level: the general factor level, the domain level,
and the test level.
To estimate the mean change in each cognitive ability
over time, we ﬁrst ran a model with the raw cognitive
scores. The models where we included the genetic pre-
dictors had the cognitive scores pre-residualised for age
in days at the time of testing and for sex. Where possible,
the analyses were run within the structural equation
model (that is, the factors of curves model and the
association with the predictors were estimated simulta-
neously). However, in some cases where the structural
equation model would not converge, we extracted factor
scores for the general factors and used linear regression
to predict them from the genetic predictors. All such
models are noted below.
We next ran the further analyses testing each PGS as a
predictor alongside (that is, controlling for) APOE e4 status,
to test for incremental predictive validity over this well-
established risk factor. We did this only for PGSs that had
shown a signiﬁcant relation to the relevant cognitive out-
come in the main analysis. Then, we included all the PGSs
together as predictors in a single model, assessing their
incremental validity over one another. For a ﬁnal analysis,
which was not part of the preregistration, we tested whether
each genetic predictor (the PGSs and APOE e4) was asso-
ciated with age-70 general cognitive ability after correcting
for the age-11 intelligence measure. In this way, we were
able to test whether each measure was predictive of cog-
nitive change across most of the life course (that is, between
ages 11 and 70).
The LBC1936 participants had a homogeneous, White
European background, and thus we did not expect
population stratiﬁcation to have a strong inﬂuence on the
results. Nevertheless, for all analyses involving relating
the PGSs (and APOE e4) to phenotypes, we included
four SNP principal components (multidimensional scal-
ing components) as covariates. We used the False Dis-
covery Rate correction [55] to adjust p-values for
multiple comparisons across the 15 predictors (14 PGSs
plus APOE e4). Structural equation modelling was per-
formed using Mplus v7.3 [56], and used full-information
maximum likelihood estimation (FIML) to use all of the
available data in each model. Foster et al. [57] recom-
mend that the missing-data technique is chosen on the
basis of its assumptions being plausibly ﬁt to a dataset;
here we operated under the “missing at random”
assumption—the basis for FIML—where patterns of
missingness were assumed not to be systematically
related to the missing cognitive scores (see discussion in
ref. [5]). All other analyses were run in R [58].
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Results
Preliminary polygenic score analyses
Eleven of the fourteen PGSs were signiﬁcantly associated
with their “own” related phenotype (see Table 1) in the
LBC1936 sample. These signiﬁcant relations ranged from
explaining 1.00% of the variance, in the case of the grip
strength PGS in predicting grip strength, to the PGS for
height explaining 13.07% of the variance in height. Three of
the scores were not signiﬁcantly related to the outcome
phenotype: the PGS for Alzheimer’s disease was not sig-
niﬁcantly correlated with the dementia-screening Mini-
Mental State Examination score (explaining 0.38% of the
variance, p= .051), the PGS for major depressive disorder
was not related to HADS depression score (explaining less
than .001% of the variance, p= 0.94), and the PGS for
stroke was not signiﬁcantly related to self-reported stroke
(explaining 0.42% of the variance, p= 0.24).
A correlation matrix of the relations among each of the
PGSs is provided in Table S1. The PGS for education
showed the highest number of signiﬁcant relations to the
other PGSs, being related to nine of the other scores; this
mostly consisted of education-linked variants being posi-
tively associated with variants linked to better health
(broadly consistent with evidence from genetic correlations;
see e.g., ref. [59]). The correlation sizes among the PGSs
were generally low: the strongest absolute relation between
any of the PGSs was that between the education and BMI
PGSs, estimated at r= –0.26. Despite its poor phenotypic
prediction of the depressive state as described above, the
PGS for major depressive disorder correlated in the
expected direction with that for neuroticism (r= 0.23) [60,
61]. As planned in the preregistration, we ran a parallel
analysis of the fourteen PGSs using the psych package for
R: this indicated that there were four factors in the data,
with no evidence for a strong “general” factor. Therefore,
we did not use any of these factors in the analyses below.
Cognitive levels and slopes
Descriptive statistics for each of the cognitive tests at each
wave, and a full correlation matrix, are provided in
Tables S3 and S4 in the Supplementary Materials, respec-
tively. The longitudinal changes, estimated from the struc-
tural equation models, for each cognitive test score are
shown in Table 2. All but two of the tests showed statisti-
cally signiﬁcant declines over time, with the largest per year
declines being seen in the processing speed tests. The two
tests showing no signiﬁcant age-related change were the
NART and verbal ﬂuency, both of which were in the
category of “crystallized” tests and were thus expected to
show less decline with age. The trajectory of each test with
age is illustrated in Fig. 2, for the model-implied trajectory
as well as the change in the raw data for comparison (see
Figure S4 for an alternative way of visualizing the data,
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Fig. 1 Simpliﬁed diagram of the structural equation model used to
estimate the general cognitive level and the general cognitive slope. A
latent growth curve was estimated across the four waves for each
cognitive test (with the numbers showing the average length between
each wave), and the levels and slopes were factor-analysed in a hier-
archical model with four cognitive domains and a general factor. Note
that, for illustrative purposes, not all tests are shown (the Speed
domain had four tests and the other domains had three each; see
Table 2). The main outcomes of interest—the association of each
polygenic score with the general level and slope variables—are indi-
cated by the dashed lines
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showing each data point). In all but one case the model-
implied trajectory was the same in sign as that in the raw
data, though some slopes were different in magnitude. For
verbal paired associates, the magnitude was reversed (it
became negative in the model). These changes are to be
expected given the use of FIML estimation in the structural
equation model: several previous methodological investi-
gations have shown that the choice of missing-data tech-
nique can inﬂuence results [54, 55].
We then factor-analysed the levels and slopes of all
the tests, as described above and shown in Fig. 1. The
baseline model (with the tests corrected for age within
the wave and sex, but with no polygenic score pre-
dictors) showed excellent ﬁt to the data, according to
multiple ﬁt indices: χ2(1298)= 2446.16, p < 0.001; root
mean square error of approximation = 0.028; compara-
tive ﬁt index= 0.968; Tucker-Lewis index= 0.967;
standardized root mean square residual= 0.057. The full
parameters for this model are shown in Figure S5 in
the Supplementary Materials. The general factor of
cognitive level explained 40.9% of the variance in per-
formance across all thirteen cognitive tests’ scores, and,
for the same tests, the general factor of cognitive slope
explained 69.7% of the variance in cognitive change
between ages 70 and 79.
Polygenic score prediction of general cognitive level
and slope
The associations of each PGS and APOE e4 with the age-70
level and age 70-to-79 slope of general cognitive ability are
shown in Table 3 and Fig. 3. Of the fourteen PGSs, seven
were statistically signiﬁcantly associated with cognitive
level at age 70: higher PGSs for education and height were
associated with higher general cognitive levels, and PGSs
for schizophrenia, coronary artery disease, type 2 diabetes,
smoking, and BMI were associated with lower general
cognitive levels. All effect sizes for these signiﬁcant effects
were modest: the standardized betas ranged from –.178 (for
smoking) to .302 (for education); the p-values that remained
signiﬁcant after multiple-comparisons correction ranged
from 1.31 × 10−20 to 0.008. APOE e4 status was also sig-
niﬁcantly associated with level: its association became non-
signiﬁcant after correction for multiple comparisons.
Only one of the PGSs, that for schizophrenia, was a
signiﬁcant (negative) predictor of general cognitive slope
Table 1 Variance explained by
each polygenic proﬁle score in
relevant Lothian Birth Cohort
1936 outcome variables
Polygenic proﬁle score Outcome variable Std. β SE p-value % Variance
explained
Educational attainment Years of education 0.276 0.031 1.55 × 10−19 7.58%
Neuroticism NEO-PI-R Neuroticism 0.176 0.038 1.85 × 10−06 2.58%
Conscientiousness NEO-PI-R
Conscientiousness
0.083 0.033 0.014 0.69%
Alzheimer’s disease MMSE –0.061 0.031 0.051 0.38%
Schizophrenia Block design –0.120 0.034 4.57 × 10−04 1.23%
Major depressive
disorder
HADS depression score 0.002 0.032 0.941 5.49 × 10−04%
Coronary artery disease Cardiovascular disease†
(24.5%)
0.267 0.076 3.94 × 10−04 1.89%
Stroke Stroke† (5.0%) 0.169 0.145 0.243 0.42%
Type 2 diabetes Type 2 diabetes† (8.6%) 0.608 0.122 7.27 × 10−07 5.79%
Smoking Smoking 0.147 0.032 5.41 × 10−06 2.05%
Height Height 0.365 0.030 1.72 × 10−34 13.07%
BMI BMI 0.359 0.031 5.78 × 10−31 11.85%
FEV1 FEV1 0.191 0.026 3.00 × 10
−13 5.21%
Grip strength Grip strength 0.065 0.020 0.002 1.00%
Standardized βs, SEs, and p-values are from general linear (continuous outcomes) or generalized linear
(categorical outcomes, indicated with the † symbol and with the percentage of the sample who reported
having, or having had, that condition at or by age 70 in parentheses) regression models adjusting for age at
the time of measuring/reporting the outcome variable, sex, and four multidimensional scaling components.
All signiﬁcant p-values remained signiﬁcant after False Discovery Rate correction. For continuous outcome
variables, the % variance explained is derived from the partial R2. For categorical outcome variables, the %
variance explained is derived from the Nagelkerke’s R2. Rows in bold survived false discovery rate
correction for multiple testing. References for the GWAS source of each polygenic score can be found in
Table S1
NEO-PI-R NEO-Personality Inventory-Revised, MMSE Mini-Mental State Examination, HADS Hospital
Anxiety and Depression Scale, FEV1 Forced expiratory volume in 1 second
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between ages 70 and 79, but this did not survive multiple-
comparisons correction. APOE e4 status, however, was a
signiﬁcant predictor of general cognitive decline—those
with one or two APOE e4 alleles had signiﬁcantly steeper
general cognitive decline than those who had none—and
this association survived multiple-testing correction.
We next tested whether the scores that had shown sig-
niﬁcant relations to the cognitive outcomes in the initial
analysis were still statistically signiﬁcantly related after
including APOE e4 as a separate predictor. Results are
shown in Table S5. In all cases, the polygenic score pre-
dictor remained signiﬁcant after adjusting for APOE
e4 status, with slightly attenuated effect sizes: that is, their
associations seemed to be largely independent of any rela-
tion with APOE e4.
Next we ran the simultaneous-predictor models, includ-
ing all PGSs predicting general cognitive level, and (in a
separate model) general cognitive slope. For general cog-
nitive level at age 70, only the signiﬁcant associations with
the PGSs for education (β= 0.217) and schizophrenia
(β= –0.109) remained (see Table S6 for full results). As in
the initial analysis, none of the PGSs were signiﬁcantly
related to general cognitive slope over time after correction
for multiple comparisons.
Note that, due to the appearance of newer (and larger)
GWAS studies during the submission and review process of
this paper, we have updated several of the PGSs. The ori-
ginal results are provided in Table S11 (for the list of
GWAS studies used for the main results in the paper, see
Table S1).
Additional (non-preregistered) analyses I: Polygenic
score prediction of lifetime cognitive change
We ran the analyses predicting general cognitive level at
age 70 adjusted for age-11 cognitive ability—that is,
predicting cognitive change across most of the life
course. The basic cognitive model is shown in Figure S6.
Note that age 11 cognitive ability was related very
strongly to age 70 general cognitive level (β= 0.814,
SE= 0.015, p= ~0.00; see ref. [5]). Results from the
genetic analyses are shown in Table 4, along with cor-
relations between each of the genetic predictors and age-
11 cognitive ability itself. Seven of the fourteen PGSs
were signiﬁcantly associated with intelligence score at
age 11 after multiple-comparisons correction: education,
schizophrenia, coronary artery disease, stroke, type 2
diabetes, smoking, and BMI. There was no association
with APOE e4. The association between lifetime cogni-
tive change and the PGS for education was signiﬁcant
(and survived multiple-testing correction), with a stan-
dardized effect size of β= .100: those with a higher PGS
for education saw relatively less cognitive change acrossTa
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Polygenic predictors of age-related decline in cognitive ability
Fig. 2 Standardized linear trajectories of each cognitive test with age.
Intercepts (at the youngest age) are set to zero for comparative pur-
poses. The horizontal dotted line indicates zero. The coloured solid
line is the model-implied trajectory (using full-information maximum
likelihood estimation); the coloured dotted line is the regression line
through the raw data (with shaded 95% conﬁdence interval)
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the lifespan. The other PGSs were not related sig-
niﬁcantly to the lifetime cognitive change variable.
In addition, we ran a follow-up analysis to further probe
this latter result (that the education PGS was related to
cognitive change across the life course). Since there is
evidence that cognitive abilities are improved by time spent
in education [62], it is of interest to include phenotypic
years of education in the analysis, and test whether the
association between the education PGS and cognitive
change is mediated by achieved years of education. We did
so in a structural equation model where the education PGS
had both a direct path to general cognitive ability at age 70,
and an indirect one via phenotypic years of education (see
Figure S7). As above, general cognitive ability at age 70
was regressed on the Moray House Test score at age 11, to
form a life course cognitive change measure. We found a
signiﬁcant, but small, mediation effect such that 6.4% of the
educational polygenic score’s relation to cognitive change
was mediated by years of education. This is consistent with
two conclusions: ﬁrst, some of the genetic effect on cog-
nitive change across the life course is independent of
achieved years of education: there was still a residual direct
path in the model. Second, the link between education and
cognitive change is not fully a genetic effect; there is still
the possibility that purely environmental effects of educa-
tion are inﬂuencing cognitive change. We are grateful to an
anonymous reviewer for suggesting this analysis; full
results from the mediation model are in Table S7.
Additional (non-preregistered) analyses II: further
investigation of the Alzheimer’s disease score
We did not expect that the Alzheimer’s disease PGS would
make such a poor prediction of general cognitive slope,
especially when APOE e4 status had made a substantial
prediction, and SNPs associated with APOE e4 featured
prominently in Alzheimer’s GWAS results. We tested
whether this was due to our use of the p= 1.00 threshold
when calculating the PGS; it is possible that inclusion of the
large number of less- and non-signiﬁcant SNPs over-
whelmed the signal from APOE e4-linked loci. Therefore,
we recalculated the Alzheimer’s disease PGS at a more
stringent threshold—p= 0.01—and re-ran the relevant
analyses. As would be expected, the more stringent PGS
had a somewhat higher (point-biserial) correlation with
APOE e4 status (r(964)= .286, p= 4.82 × 10−21) than did
the PGS with the p= 1.00 threshold (r(963)= 0.117, p=
2.73 × 10−04). The more stringent Alzheimer’s PGS also
made a signiﬁcant prediction of the slope of general cog-
nitive decline (β= –0.109, SE= 0.043, p= 0.012), though
not its initial level (β= –0.056, SE= 0.035, p= 0.110).
For comparison, we also recalculated the other PGSs at
the p= 0.01 threshold. The results for all p= 0.01 PGSs are
shown in Table S8. Most results were similar: unlike the
Alzheimer’s result reported above, all other non-signiﬁcant
associations with general cognitive slope remained non-
signiﬁcant with this new threshold. The predictions for
Table 3 Associations of each
polygenic proﬁle score, and
APOE e4 status, with general
cognitive level (age 70) and
slope (age 70–79) in individual-
predictor models
Genetic variable Association with baseline g Association with g slope
Std. β SE p-value Std. β SE p-value
APOE e4 –0.153 0.068 0.025 –0.319 0.068 3.44 × 10−06
Education 0.302 0.032 1.31 × 10−20 0.006 0.044 0.888
Neuroticism –0.077 0.039 0.047 –0.004 0.048 0.929
Conscientiousness –0.017 0.035 0.634 0.015 0.044 0.726
Alzheimer’s disease –0.017 0.035 0.634 –0.073 0.044 0.094
Schizophrenia –0.148 0.038 1.07 × 10-04 –0.110 0.048 0.022
Major depressive disorder –0.037 0.035 0.290 –0.008 0.044 0.856
Coronary artery disease –0.108 0.035 0.002 –0.011 0.044 0.808
Stroke –0.056 0.035 0.109 –0.016 0.043 0.719
Type 2 diabetes –0.089 0.035 0.012 –0.010 0.045 0.826
Smoking –0.178 0.035 3.66 × 10-07 –0.035 0.045 0.438
Height 0.093 0.035 0.008 0.009 0.045 0.833
BMI –0.135 0.036 1.76 × 10-07 0.028 0.045 0.540
FEV1 0.074 0.037 0.048 0.051 0.047 0.277
Grip strength –0.041 0.036 0.255 0.035 0.044 0.425
All estimates come from hierarchical latent growth curve structural equation models. Associations are
corrected for age at cognitive testing, sex, and four multidimensional scaling components. Bold values are
those that were statistically signiﬁcant after false discovery rate correction for multiple testing. Note that the
results for APOE e4 were estimated using extracted factor scores in linear regression models; all other effect
sizes were estimated within the structural equation models themselves
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cognitive level generally had similar effect sizes, though the
association between level and coronary artery disease was
no longer signiﬁcant, whereas the nominally-signiﬁcant
associations for the height PGS did not survive multiple
comparisons correction.
Additional (non-preregistered) analyses III:
comparing genotypic and phenotypic prediction
A reviewer of the manuscript suggested that we compare
the polygenic score predictions of cognitive ageing to the
predictions made from their associated phenotypes. To this
end, we took the phenotypes that were related to the poly-
genic scores above (under “preliminary polygenic score
analyses”) and used them to predict general cognitive level
and slope. The results, and comparisons using Williams’s
test, are shown in Table S9. For level, some polygenic
scores made near-identical predictions as their associated
phenotype: this was the case for coronary artery disease,
type 2 diabetes, smoking, height, and BMI. For education,
neuroticism, and Alzheimer’s disease, the phenotype was a
substantially better predictor than the polygenic score. For
slope, all effect sizes were small, and the only signiﬁcant
phenotypic predictor after correction was that of the MMSE
score (used as the Alzheimer’s-related phenotype); higher
MMSE scores predicted slightly healthier cognitive ageing
over time.
Additional (non-preregistered) analyses IV:
competing mortality risks across polygenic scores
Given that many of the LBC1936 members died during the
progress of the longitudinal study, it is of interest to con-
sider whether the competing risk of mortality that is
potentially conferred by differences in some of the poly-
genic scores [32] might explain the null associations found
above. To this end, as an additional analysis, we used the
suite of polygenic scores, and APOE e4 status, to predict
mortality (for which data were collected via the National
Health Service’s Central Register, provided by the National
Records of Scotland and provided to the LBC1936 team on
approximately a 12-week basis). In the sample of 1,005
participants where polygenic scores were available, there
had been 277 deaths (~25% of the starting sample) by the
most recent update (April 2017). The average age at death
was 77.00 years (SD= 3.37). The results are shown in
Table S10: of the scores, only one—that for higher BMI—
was signiﬁcantly associated with a greater risk of earlier
death, and this association was not signiﬁcant after false
discovery rate correction. In addition, we tested whether
individuals who went on to die before the end of the follow-
up period had a lower general intelligence at age 70, and a
steeper slope of cognitive decline, but neither of these
reached statistical signiﬁcance (level: β= –0.062, SE=
0.035, p= 0.078; slope: β= –0.045, SE= 0.027, p=
0.095). Overall, then, there was little evidence of mortality-
speciﬁc dropout being a strong biasing factor in the cog-
nitive function-based results presented here.
Discussion
The study reported here was an attempt to shed light on the
genetic links between cognitive ageing and a range of traits
and disorders by performing polygenic score prediction of
age-related cognitive decline. All the PGSs were chosen a
priori to index genetic variants associated with key ageing-
relevant traits and conditions. Some of these PGSs were
associated with the baseline cognitive level at age 70, and
the education PGS was associated with cognitive change
from age 11 to age 70. However, all of the PGSs had small,
non-signiﬁcant relations with the gradient of the general
cognitive slope (based on a general cognitive decline vari-
able that explained over two-thirds of the slope variance
across all thirteen tests) between age 70 and 79. The pre-
sence of the APOE e4 allele, on the other hand, made more
Fig. 3 Associations of APOE e4 status and each polygenic score with
cognitive level (age 70) and cognitive decline (age 70–79). *= Sta-
tistically signiﬁcant after false-discovery rate correction. †=Nomin-
ally signiﬁcant, but no longer signiﬁcant after false-discovery rate
correction. Note that the effect for APOE e4 is standardized only with
respect to the outcome (with a dichotomous predictor); all other effect
sizes are standardized with respect to both the outcome and the
predictor
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substantial predictions of cognitive decline: having either
one or two alleles, compared to zero, explained around 10%
of the variance in the slope of cognitive decline between age
70 and 79. None of the PGSs approached this level of effect
size. Below, we discuss some of the implications, strengths,
and limitations of the study.
Overall, the results were similar to results from studies
attempting to use phenotypic data to predict cognitive
decline (e.g. attempts in this same sample over a shorter
period of change [5]): cognitive levels could be predicted
with far larger effect sizes than cognitive slopes. It should
be noted that some of the PGS correlations with cognitive
level were similar or larger in effect size to those using the
actual phenotypes themselves (see Table S9). For example,
phenotypic BMI had a correlation of –0.130 with cognitive
level at 70; the equivalent for the BMI PGS was –0.135.
This similarity in the phenotypic and genotypic effect sizes
was also the case for coronary artery disease, height,
smoking, and type 2 diabetes. This was not, however, the
case for predicting slope, where few if any variables showed
substantial predictive effect sizes, and effect sizes were
similarly small for both genotypic and phenotypic
predictors.
It may be that any genetic effects indexed by the PGS
occur at different points in the life course. For instance,
variants linked to education and BMI—two PGSs that were
signiﬁcantly associated with baseline cognitive level, but
not slope—may have their effects on cognitive ability
during childhood or early adulthood, whereas any effects of
APOE e4—which signiﬁcantly predicted slope, but not
level—may appear only within older age. In one GWAS of
general cognitive ability [63], the effect of APOE e4 was
particularly pronounced at older ages, consistent with these
ﬁndings (see ref. [64] for a longitudinal analysis in an even
older sample, and ref. [65] for an investigation of age-
dependent pleiotropy among cognitive traits and psychiatric
disorders). Note that any PGS associations reported herein
were independent of APOE e4, as per our simultaneous
regression analysis including them both as predictors.
The PGSs that were associated at with cognitive ability
level at age 70 were generally the same as those that showed
associations at age 11 (that is, those for education, schizo-
phrenia, coronary artery disease, stroke, type 2 diabetes,
smoking, and BMI); however, only the PGS for education
showed an association with later ability after correcting for
early ability—that is, only the PGS for education was cor-
related with lifetime cognitive change. This result implies
that education-linked variants are related to changes in
cognitive abilities before older age (speciﬁcally, before age
70). These ﬁndings are of relevance to the concept of
“cognitive reserve” [13]: they imply that researchers who
ﬁnd links between early-life education and later-life cog-
nitive abilities (or cognitive change) should take into
account the fact that some of the effect may come from a
genetic propensity to better educational attainment, and not
the educational attainment itself.
Table 4 Associations of each
polygenic score and APOE
e4 status with age 11
intelligence and lifetime
cognitive change (age 70 general
intelligence (g) adjusted for age
11 intelligence)
Genetic variable Association with age 11
intelligence
Association with age 70 g,
adjusted for age 11 intelligence
Std. β SE p-value Std. β SE p-value
APOE e4 .024 .074 .740 –.080 .055 .141
Education .321 .032 2.11× 10-24 .100 .026 1.01× 10-04
Neuroticism –.032 .037 .377 –.016 .027 .563
Conscientiousness .010 .033 .741 –.171 .119 .153
Alzheimer’s disease .012 .033 .692 –.033 .025 .174
Schizophrenia –.136 .036 1.85× 10-04 –.021 .028 .446
Major depressive disorder .028 .033 .389 –.032 .025 .191
Coronary artery disease –.098 .032 .003 –.039 .025 .116
Stroke –.075 .032 .022 .016 .025 .523
Type 2 diabetes –.079 .033 .019 –.010 .025 .703
Smoking –.187 .033 2.60× 10-08 –.023 .026 .369
Height .063 .033 .056 .013 .025 .595
BMI –.164 .034 2.15× 10-06 .001 .079 .989
FEV1 .055 .035 .113 .023 .026 .380
Grip strength –.030 .033 .362 –.002 .025 .927
Note: Lifetime change come from a hierarchical latent model of general cognitive ability, comprising tests
taken at age 70 (Figure S3), with the g-factor adjusted for age 11 intelligence. Rows in bold are effects that
survived (per-column) false discovery rate correction for multiple testing. All models included four principal
components to adjust for population stratiﬁcation
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It may simply take a higher-powered study, with more
participants, longer follow-up times, and additional waves,
to detect genetic effects with the small sizes of those sug-
gested here. On the other hand, as was noted above, larger
GWAS studies have tended to produce PGSs with better
predictive validity [27], and this will probably also be the
case for future iterations of the PGSs studied here. Another
reason for the small-sized predictions may be because the
phenotypes linked to the PGSs do not themselves reliably
predict cognitive decline. The most recent systematic
review [10] noted that much of the evidence in this sphere is
weak; we do not have a strong, multi-study evidence base
for many of the phenotypic—let alone genetic—predictors
of cognitive decline discussed here. It is also possible that
genetic propensities interact with environments in ways
that improve or worsen the cognitive ageing trajectory. Note
that there is no existing large, well-powered GWAS of
cognitive decline in particular, since there are too few
samples with the relevant variables for such a GWAS to be
run. Should such a study appear in future, we would expect
to derive a PGS that would predict cognitive decline in
independent samples.
The case of the Alzheimer’s PGS warrants further con-
sideration. As noted above, we chose to calculate all PGSs
at the most liberal, whole-genome threshold (p= 1.00),
including the effects of all SNPs, rather than a more
restricted set. The choice of just one single threshold was to
avoid the overﬁtting that often comes with choosing many
thresholds and reporting the one with the highest associa-
tion with the outcome trait of interest. However, the fact that
the prediction of cognitive decline by APOE e4 status was
so much larger than that of the Alzheimer’s PGS, which
itself contains the effect of (SNPs in linkage disequilibrium
with) APOE e4, suggested that the effects of the other SNPs
—less signiﬁcantly or not signiﬁcantly related to cognitive
decline—included in the PGS were overpowering the
APOE e4-linked signal. This appeared to the be the case: the
use of a more conservative threshold improved the pre-
dictive validity. This was not the case for the education
PGS, however: it may be that, for traits that have even
higher levels of polygenicity—for which there are no large-
effect variants such as APOE e4 for Alzheimer’s—the PGS
threshold matters less. As we noted above, larger GWASs
of Alzheimer’s disease will produce summary data with
more signals from non-APOE-e4-linked variants, and these
should be tested for their association with normal-range
cognitive ability and cognitive decline at different thresh-
olds; we note that a previous study [66] found no relation
between a PGS calculated from an older Alzheimer’s
GWAS and cognitive abilities in this same sample (see also
ref. [67] for an example of a combination of APOE and PGS
variables). Alternatively, performing a permutation test as
described in ref. [51] (Supplementary Note 4) would allow
the calculation of an empirical p-value threshold, potentially
allowing for a better prediction than we had with our across-
the-board use of the p= 1.00 threshold. Generally, how-
ever, there are as yet no hard-and-fast rules for the use of
PGSs by researchers who wish to maximise their predictive
ability but are concerned about multiple-comparisons test-
ing; ref. [68] provides some recommendations.
Another strategy to improve prediction would be to
follow the approach of ref. [69], where the authors took a
much larger set of eighty-one PGSs and used them as pre-
dictors of the levels of various traits including cognitive
ability and BMI (they used a sample of younger individuals
and thus could not examine cognitive decline). They ran
their analysis using penalized regression (speciﬁcally the
Elastic Net [70]), which allowed the large number of PGS
variables to be reduced to the best set of predictors, and
allowed them to explain a somewhat larger proportion of
the variance in the traits. Such an hypothesis-free method,
using algorithmic selection from many predictors, rather
than manually choosing those predictors on the basis of pre-
existing links to cognitive decline, as we did here, may be a
more fruitful approach for prediction (if not theoretical
understanding). Finally, given the evidence that risk for
particular conditions increases substantially at the very high
end of some polygenic score distributions [71], it may be
possible in a larger sample than the one used in the present
study to isolate individuals with extreme polygenic scores
related to, for example, speciﬁc disorders, and investigate
whether they show pronounced rates of cognitive decline.
Strengths and limitations
The LBC1936 sample is a rare dataset in that it is a narrow-
age sample (all participants were from a single year of birth)
in which the follow-up waves cover nearly a decade within
older age, with thirteen high-quality cognitive tests mea-
sured repeatedly and identically; moreover, and highly-
unusually for an ageing study, it has well-validated cogni-
tive test data from age 11. Using longitudinal structural
equation modelling, we estimated general factors of cog-
nitive level and slope that removed any measurement error
associated with the individual tests and produced an index
of overall cognitive ability and its ageing. Overall, this was
a powerful way to assess cognitive decline, and we used a
variety of PGSs from varied traits and disorders in an
attempt to predict that decline’s variance. However, there
are limitations to the study.
The self-selecting nature of the LBC1936 participants
may have biased our results. That is, the participants were
generally healthy, independently-living older adults and—
by virtue of the fact they were able and interested to attend
the initial testing—were healthier and more intellectually-
engaged than the average person of their age. Non-random
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dropout, a problem for most longitudinal studies of ageing,
compounds this issue: individuals who remained in the
study across the four waves were healthier on average than
those who dropped out. We thus probably missed indivi-
duals with the poorest health and, consequently, with the
greatest degree of cognitive decline. This limitation—a
restriction of range to the higher end of the health dis-
tribution—may have contributed to our lack of ability to
predict cognitive decline in our sample.
There may also be additional complexities in the cog-
nitive decline paths that we did not consider here, since
we focused on the relatively simple linear average tra-
jectories. For example, there may be nonlinear trajec-
tories, or multiple latent trajectories (see e.g., ref. [72])
within the dataset that, if analysed in future, may reveal
differential relations to the genetic predictors. Finally, in a
few cases, the complexity of the structural equation
models meant that convergence could not be achieved
without ﬁxing some of the paths that were intended to be
freely-estimated (see Figure S2), and in some cases
without extracting factor scores and using them in linear
regression models instead of estimating all relations
within latent-variable space (i.e., simultaneously to the
estimation of the relevant structural equation model). We
would not estimate that these issues would have changed
our results to a great extent, but the latter practice
(extracting factor scores) may have led to slight altera-
tions to some of the standard errors we reported.
Conclusions
A key goal of cognitive ageing research is to be able to
predict who will experience steeper general cognitive
decline. It is also of interest to build up a picture of which
traits and disorders may share a genetic aetiology with
variations in cognitive ageing. In this study of a high-
quality, longitudinal dataset, we attempted to provide evi-
dence on both of these questions using a panel of polygenic
scores: however, despite substantial associations of several
polygenic scores (those for education, schizophrenia, cor-
onary artery disease, smoking, height, and BMI) with
general cognitive level at baseline, and the relation of the
education PGS to cognitive change between age 11 and age
70, none of the scores made useful, or even statistically
signiﬁcant, predictions of subsequent cognitive decline
across the eighth decade of life in the preregistered ana-
lyses. Future, larger GWASs might furnish us with sum-
mary statistics to produce more predictive PGSs, and
different analytic methods might increase the predictive
value of those we already have. Given that it is possible to
formulate so many PGSs from only DNA, the approach
retains its potential as an efﬁcient and protean source of
predictors. For the time being, however, the ﬁndings sug-
gest that researchers interested in genetic prediction of
longitudinal variability in cognitive ageing will derive more
value from established predictors, such as APOE e4, than
newer methods such as polygenic scores.
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